Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients

Breast Cancer Research

Volumn 16, Issue 2, 2014, Pages

  Lustberg, Maryam B ^a,d   Balasubramanian, Priya ^b   Miller, Brandon ^b   Garcia Villa, Alejandra ^b   Deighan, Clayton ^b   Wu, Yongqi ^b   Carothers, Sarah ^a,d   Berger, Michael ^a,d   Ramaswamy, Bhuvaneswari ^a,d   Macrae, Erin R ^a,d   Wesolowski, Robert ^a,d   Layman, Rachel M ^a,d   Mrozek, Ewa ^a,d   Pan, Xueliang ^e   Summers, Thomas A ^c   Shapiro, Charles L ^a,d   Chalmers, Jeffrey J ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b The Ohio State University   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BIOLOGICAL MARKER; CD45 ANTIGEN; CELL SURFACE MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; VIMENTIN; CD68 ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; CD68 ANTIGEN, HUMAN; CELL ADHESION MOLECULE; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR-ASSOCIATED ANTIGEN GA733;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BREAST METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL POPULATION; CELL SORTER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; AGED; BREAST CANCER; BREAST CANCER CELL LINE; CORRELATION ANALYSIS; FEMALE; BLOOD; BREAST TUMOR; IMMUNOHISTOCHEMISTRY; MCF 7 CELL LINE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TUMOR CELL LINE; TUMOR EMBOLISM;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-18; KERATIN-19; KERATIN-8; MCF-7 CELLS; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VIMENTIN;

EID: 84899491673     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3622     Document Type: Article

References (38)

1. van de Stolpe A, Pantel K, Sleijfer S, Terstappen LWWM, den Toonder JMJ. Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res 2011, 71:5955-5960. 10.1158/0008-5472.CAN-11-1254, 21896640.
2. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14:818-829. 10.1016/j.devcel.2008.05.009, 18539112.
3. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LWWM, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791. 10.1056/NEJMoa040766, 15317891.
4. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239. 10.1038/nature06385, 3090667, 18097410.
5. Mayer JA, Pham T, Wong KL, Scoggin J, Sales EV, Clarin T, Pircher TJ, Mikolajczyk SD, Cotter PD, Bischoff FZ. FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform. Cancer Genet 2011, 204:589-595. 10.1016/j.cancergen.2011.10.011, 22200084.
6. Pachmann K, Dengler R, Lobodasch K, Fröhlich F, Kroll T, Rengsberger M, Schubert R, Pachmann U. An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer. J Cancer Res Clin Oncol 2008, 134:59-65.
7. Hoshino K, Huang YY, Lane N, Huebschman M, Uhr JW, Frenkel EP, Zhang X. Microchip-based immunomagnetic detection of circulating tumor cells. Lab Chip 2011, 11:3449-3457. 10.1039/c1lc20270g, 3379551, 21863182.
8. Institut Curie: CirCé01 Study Evaluation of the use of circulating tumour cells to guide chemotherapy from the third line of chemotherapy for metastatic breast cancer. ClinicalTrials.gov Identifier: NCT01349842. http://clinicaltrials.gov/show/NCT01349842, Institut Curie: CirCé01 Study.
9. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res 2007, 13:920-928. 10.1158/1078-0432.CCR-06-1695, 17289886.
10. Balasubramanian P, Lang JC, Jatana KR, Miller B, Ozer E, Old M, Schuller DE, Agrawal A, Teknos TN, Summers TA, Lustberg MB, Zborowski M, Chalmers JJ. Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PLoS One 2012, 7:e42048. 10.1371/journal.pone.0042048, 3406036, 22844540.
11. Jatana KR, Balasubramanian P, Lang JC, Yang L, Jatana CA, White E, Agrawal A, Ozer E, Schuller DE, Teknos TN, Chalmers JJ. Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results. Arch Otolaryngol Head Neck Surg 2010, 136:1274-1279. 10.1001/archoto.2010.223, 3740520, 21173379.
12. Lustberg M, Jatana KR, Zborowski M, Chalmers JJ. Emerging technologies for CTC detection based on depletion of normal cells. Recent Res Cancer Res 2012, 195:97-110.
13. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339:580-584. 10.1126/science.1228522, 3760262, 23372014.
14. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012, 7:e33788. 10.1371/journal.pone.0033788, 3346739, 22586443.
15. Lara O, Tong X, Zborowski M, Chalmers JJ. Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol 2004, 32:891-904. 10.1016/j.exphem.2004.07.007, 15504544.
16. Yang L, Lang JC, Balasubramanian P, Jatana KR, Schuller D, Agrawal A, Zborowski M, Chalmers JJ. Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng 2009, 102:521-534. 10.1002/bit.22066, 3906726, 18726961.
17. Chalmers JJ, Xiong Y, Jin X, Shao M, Tong X, Farag S, Zborowski M. Quantification of non-specific binding of magnetic micro- and nanoparticles using cell tracking velocimetry: implication for magnetic cell separation and detection. Biotechnol Bioeng 2010, 105:1078-1093. 3556736, 20014141.
18. Balasubramanian P, Yang L, Lang JC, Jatana KR, Schuller D, Agrawal A, Zborowski M, Chalmers JJ. Confocal images of circulating tumor cells obtained using a methodology and technology that removes normal cells. Mol Pharm 2009, 6:1402-1408. 10.1021/mp9000519, 2829323, 19445481.
19. Tong X, Yang L, Lang JC, Zborowski M, Chalmers JJ. Application of immunomagnetic cell enrichment in combination with RT-PCR for the detection of rare circulating head and neck tumor cells in human peripheral blood. Cytometry B Clin Cytom 2007, 72B:310-323.
20. Rosenblatt JI, Hokanson JA, McLaughlin SR, Leary JF. Theoretical basis for sampling statistics useful for detecting and isolating rare cells using flow cytometry and cell sorting. Cytometry 1997, 27:233-238. 10.1002/(SICI)1097-0320(19970301)27:3<233::AID-CYTO4>3.0.CO;2-F, 9041111.
21. Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. Cytometry 1998, 34:61-70. 10.1002/(SICI)1097-0320(19980415)34:2<61::AID-CYTO1>3.0.CO;2-F, 9579602.
22. Donnenberg AD, Donnenberg VS. Rare-event analysis in flow cytometry. Clin Lab Med 2007, 27:627-652, viii. 10.1016/j.cll.2007.05.013, 17658410.
23. Zimmerlin L, Donnenberg VS, Donnenberg AD. Rare event detection and analysis in flow cytometry: bone marrow mesenchymal stem cells, breast cancer stem/progenitor cells in malignant effusions, and pericytes in disaggregated adipose tissue. Methods Mol Biol 2011, 699:251-273. 10.1007/978-1-61737-950-5_12, 21116987.
24. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010, 107:18392-18397. 10.1073/pnas.1012539107, 2972993, 20930119.
25. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Matera J, Miller MC, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC). J Clin Oncol 2005, 23(16 Suppl):503.
26. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LWWM, Hayes DF. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403-6409. 10.1158/1078-0432.CCR-05-1769, 17085652.
27. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LWWM. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12:4218-4224. 10.1158/1078-0432.CCR-05-2821, 16857794.
28. Pantel K, Alix-Panabières C. The clinical significance of circulating tumor cells. Nat Clin Pract Oncol 2007, 4:62-63.
29. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, Isaacs C. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009, 27:5153-5159. 10.1200/JCO.2008.20.6664, 19752342.
30. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, Thompson EW. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 2008, 25:629-642. 10.1007/s10585-008-9170-6, 18461285.
31. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009, 101:61-66. 10.1093/jnci/djn419, 2639293, 19116383.
32. Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, on behalf of the DETECT study group Prognostic impact of circulating tumor cells assessed with the Cell Search System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012, 14:R118. 10.1186/bcr3243, 3680931, 22894854, on behalf of the DETECT study group.
33. Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013, 137:503-510. 10.1007/s10549-012-2382-0, 23271327.
34. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012, 23:1144-1150. 10.1093/annonc/mdr434, 21965473.
35. Jiang ZF, Cristofanilli M, Shao ZM, Tong ZS, Song EW, Wang XJ, Liao N, Hu XC, Liu Y, Wang Y, Zeng L, Zhang M. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. Ann Oncol 2013, 24:2766-2772. 10.1093/annonc/mdt246, 23857960.
36. Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, de Santis M, Zeillinger R, Hudec M, Dittrich C. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol 2011, 50:700-710. 10.3109/0284186X.2010.549151, 21261508.
37. Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, Goodman JC, Groves MD, Marchetti D. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 2013, 5:180ra148. A published erratum appears in Sci Transl Med 2013, 5:189er5.
38. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011, 1:54-67. 10.1158/2159-8274.CD-10-0028, 3203524, 22039576.